Novaremed Announces Closing of a New Financing, Publication of PCT Patent Application and Participation at IASP Virtual Conference on Pain & Expo
15.9.2020 11:22:00 EEST | Business Wire | Press release
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has raised CHF2.5 million from its existing shareholders in an oversubscribed new financing round. This brings the total financing raised by the company, since its inception, to CHF23.5 million. The additional proceeds will be used to prepare for the initiation of a Phase 2b clinical study in the US of its novel drug candidate, NRD135S.E1, for the treatment of Painful Diabetic Peripheral Neuropathy (PDPN). The U.S. Food and Drug Administration (FDA) had recently cleared an Investigational New Drug (IND) application for the Phase 2b clinical study.
“The oversubscription of the new financing is a strong endorsement by our shareholders of the major milestone achieved by the company by securing an IND clearance from the FDA”, said Subhasis Roy, M. Com, MBA, CEO/COO of Novaremed.
Novaremed also announced today that its PCT patent application covering a targeted therapy to treat pain and inflammation was published on July 30, 2020 (Publication No. WO 2020/1522226). It was titled “Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity”. This PCT application allows Novaremed to file patent applications and seek protection in most major countries worldwide. The national patent applications, if granted, will provide protection for Novaremed’s technology without a gap in patent protection until 2039/40.
Dr. Eli Kaplan, Novaremed’s Founder and Chief Innovator, commented, “This PCT patent application is a significant step in being able to protect our unique compound for neuropathic pain for many years to come. It is particularly important now as we get closer to beginning our Phase 2b clinical trial in patients with PDPN.”
Novaremed is participating at International Association for the Study of Pain (IASP) sponsored conference “Virtual Series on Pain & Expo”, which is being held virtually this year between September 2020 and March 2021. Novaremed’s poster abstract on the results of the Phase 2a Proof of Concept study has been accepted for the virtual poster gallery.
Notes to the Editor:
About Novaremed
Novaremed Ltd, a wholly owned subsidiary of Novaremed AG was founded in 2008 in Israel and Novaremed AG was founded in 2017 in Switzerland. Novaremed Ltd is developing NRD135S.E1, an orally active non-opioid small molecule with a novel mechanism of action against PDPN. In a Phase 2a Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2b study in PDPN patients in USA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005582/en/
Contact information
For further information about Novaremed, please contact:
Subhasis Roy, CEO/COO
Tel: +41 79 2075715
Email: subhasis.roy@novaremed.com
www.novaremed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hytera Advances AI-Powered Critical Communications at Global Partner Summit 202612.5.2026 15:41:00 EEST | Press release
Hytera Communications, a leading global provider of critical communications technologies and solutions, successfully concluded its annual Global Partner Summit (HGPS) 2026 on May 8 in Shanghai. Held under the theme “Advancing Together,” the summit brought together more than 500 attendees from over 60 countries to strengthen collaboration, share strategic insights, and explore future opportunities in AI-powered critical communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512161109/en/ Yelin Jiang, CEO of Hytera Group, delivering the keynote speech at HGPS 2026 in Shanghai. Reflecting on Hytera’s development from 2025 to 2026, Yelin Jiang, CEO of Hytera Group, shared his outlook on the company’s future growth and innovation strategy. “Looking back on 2025, we grew in business and market, grew in technology, and grew together with our partners,” said Jiang. “Building on that momentum, we are now advancing together
NetApp Collaborates with Red Hat to Help Advance Data Protection and Scale for Red Hat OpenShift Deployments12.5.2026 15:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced new NetApp data management capabilities optimized for Red Hat OpenShift that enable advanced levels of resilience and scale for virtualized environments, on-premises and in the cloud. The updates improve the speed and predictability of backup, recovery, and day-to-day operations so customers can migrate, scale, and manage virtual machine (VM) and container environments to enable innovation and agility with greater confidence. According to The state of virtualizationreport from Red Hat, 90 percent of organizations agree that virtualization supports innovation. Combined with the report’s finding that 71 percent of organizations have over half of their IT infrastructure virtualized, enterprises are expanding their virtualized environments to help them manage the increasing volumes of data that fuel the AI-era. As Red Hat OpenShift virtualized environments grow, backup methods that rely on scanning full VM
Telehouse Canada Undergoes Major Infrastructure Upgrade to Scale AI-Driven Organizations12.5.2026 15:00:00 EEST | Press release
Telehouse Canada, a leading data centre service provider and subsidiary of KDDI Corporation, has announced the completion of a major infrastructure upgrade designed to support the next generation of AI‑driven workloads. By introducing direct liquid‑to‑chip technology, Telehouse enables high‑density AI inference deployments within its interconnection‑rich downtown Toronto data centre environments—reinforcing the company’s leadership in delivering resilient, future‑ready facilities that power Canada’s digital transformation and support the next wave of innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512456773/en/ Telehouse Canada's Advanced Cooling Framework As AI adoption accelerates across industries, organizations are increasingly seeking data centre environments capable of supporting performance‑intensive workloads at scale. These requirements are driving demand for higher‑density infrastructure and advanced
White Circle’s AI Control Platform Raises $11m from Industry Giants After Founder Goes Viral for Exposing Safety Flaw in Biggest AI Models12.5.2026 14:19:00 EEST | Press release
White Circle – the platform trusted by global brands to keep their AI models in check – has raised $11m from some of the biggest names in the industry including Romain Huet (OpenAI); Dirk Kingma (ex-OpenAI, now Anthropic); Guillaume Lample (Mistral); Thomas Wolf (Hugging Face); Olivier Pomel (Datadog); François Chollet (Keras); Mehdi Ghissassi (ex-DeepMind); Paige Bailey (DeepMind); and David Cramer (Sentry). The Seed funding will be used to further accelerate product development, expand its team across the US, UK and Europe and grow White Circle's global customer base. As firms look to capitalise on the AI boom; with vibe coding letting anyone ship AI products in an instant; and with increased reports of AI models breaking free from their safety rails, White Circle is the only all-in-one, enterprise-grade platform that tests, protects, observes and improves AI in real time. It was founded by engineer Denis Shilov who went viral in 2024 when he bypassed the safety filters of every majo
Glooko and mylife Diabetes Care Expand Diabetes Data Management Partnership12.5.2026 14:00:00 EEST | Press release
Glooko, Inc. and mylife Diabetes Care today announced an agreement to further expand their partnership, under which Glooko will serve as mylife Diabetes Care’s primary data management platform for mylife products. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512745029/en/ This next step builds on the strong, well-established collaboration between the two companies, ensuring continuity in the way healthcare professionals and patients access data from mylife products, including mylife Loop, an automated insulin delivery (AID) solution powered by mylife CamAPS FX from CamDiab. It also strengthens the shared commitment of both companies to supporting day-to-day clinical practice and improving outcomes. “Diabetes care is increasingly connected, and data management is one of the most important layers in helping people with diabetes and care teams make sense of information across devices and therapies,” said Mike Alvarez, Chie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom